Eryn Berry
Endocrinology, Diabetes & Metabolism · Scottsdale, AZNPI 1609127398
Payments from drug & device makers
Across 216 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$742
- Novo Nordisk$555
- Radius Health, Inc.$285
- AbbVie$262
- Corcept Therapeutics$232
- Amgen$197
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,272100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 43 | $742 |
| Novo Nordisk | 33 | $555 |
| Radius Health, Inc. | 14 | $285 |
| AbbVie | 14 | $262 |
| Corcept Therapeutics | 8 | $232 |
| Amgen | 12 | $197 |
| Xeris Pharmaceuticals, Inc. | 10 | $170 |
| Boehringer Ingelheim | 8 | $167 |
| Sequel Med Tech, LLC | 1 | $147 |
| Dexcom, Inc. | 6 | $145 |
| Antares Pharma, Inc. | 7 | $125 |
| Cequr Corporation | 3 | $122 |
| Madrigal Pharmaceuticals | 4 | $114 |
| Abbott | 4 | $97 |
| Bayer | 5 | $78 |
| Insulet Corporation | 5 | $76 |
| Halozyme Inc | 4 | $76 |
| Novartis | 3 | $68 |
| Verity Pharmaceuticals Inc. | 3 | $61 |
| Recordati_rare_diseases_inc. | 3 | $58 |
| Amneal Pharmaceuticals LLC | 3 | $50 |
| AstraZeneca | 2 | $48 |
| Sanofi-aventis U.S. LLC | 3 | $38 |
| Mannkind Corporation | 2 | $37 |
| Tandem Diabetes Care, Inc. | 2 | $35 |
| Medtronic | 2 | $34 |
| Amphastar Pharmaceuticals, Inc. | 2 | $33 |
| Sandoz | 1 | $31 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Globus Medical | 1 | $25 |
| Ascensia Diabetes Care US Inc. | 1 | $24 |
| Amryt Pharma Holdings Ltd | 1 | $23 |
| Soleno Therapeutics, Inc. | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,272 in reported general payments places this provider in the 55th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 148 | $245,376 |
| JardianceEmpagliflozin | 68 | $86,724 |
| MounjaroTirzepatide | 57 | $73,615 |
| Tresiba Flextouch U-200Insulin Degludec | 51 | $52,531 |
| Tresiba Flextouch U-100Insulin Degludec | 47 | $36,830 |
| TrulicityDulaglutide | 18 | $35,574 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 45 | $33,454 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $19,546 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $17,403 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $15,662 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 11 | $10,781 |
| SynthroidLevothyroxine Sodium | 61 | $5,947 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 54 | $5,844 |
| Humalog Kwikpen U-100Insulin Lispro | 17 | $5,613 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $5,495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $555 | $250,721166 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $742 | $115,719104 claims |
| Boehringer IngelheimJardiance | $167 | $86,72468 claims |
| AbbVieSynthroid | $262 | $5,94761 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $50 | $2,163212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Scottsdale
- Amir HarariScottsdale$361K
- Kristina BlohmScottsdale$220K
- Andrea FerencziScottsdale$137K
- Abdul Razzak AlamirScottsdale$34K
- Sreedevi ReddyScottsdale$28K
- Grace Zlaket MattaScottsdale$17K
- Heather SaranScottsdale$14K
- Chandana MishraScottsdale$11K
- Vincent LiouScottsdale$10K
- Kimberlee BrontsemaScottsdale$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.